Ovarian Cancer
Amoy Diagnostics, AstraZeneca Partner to Advance PARP Inhibitor CDx For Maintenance Indication
AmoyDx's test, if approved, would identify patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer who are eligible for maintenance treatment.
Aspira's Stock Plummets on New $4.7M Registered Direct Offering
Shares were down as much as 34 percent after the company announced the registered direct offering of 1,694,820 shares of common stock.
Aspira Women's Health Licenses Dana-Farber microRNA Signature; Firm Executes Reverse Stock Split
Aspira Women's Health has been evaluating Dana-Farber's microRNA technology for ovarian cancer detection since early 2021.
Mercy BioAnalytics Raises $41M in Series A Financing
The proceeds will help develop and commercialize its extracellular vesicle-based Mercy Halo platform for lung, ovarian, and other cancer screening tests.
GenoMe Diagnostics Preparing Digital PCR-Based Ovarian Cancer Test for US, EU, UK Submissions
Premium
The Belfast, Northern Ireland-based company also believes its technology could be used to create other early-stage detection tests for multiple cancers.